The biotechnology sector is hailing a major milestone as Isomorphic Labs, a startup incubated by Google DeepMind, prepares to enter human trials with a drug candidate designed using artificial intelligence (AI). Industry experts see this breakthrough as a potential game-changer in biomedical research and development.